Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew I Milowsky

Showing results (151-160 of 205) with videos related to

Pageof 21
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 21, 2022
Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO GuidelineW Kimryn Rathmell, R Bryan Rumble, Peter J Van Veldhuizen, et al.
Journal for Immunotherapy of Cancer|August 16, 2017
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinomaAshish M Kamat, Joaquim Bellmunt, Matthew D Galsky, et al.
Acta Oncologica (Stockholm, Sweden)|August 31, 2017
Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) InvestigatorsJihane Boustani, Aurélie Bertaut, Matthew D Galsky, et al.
British Journal of Cancer|July 23, 2021
Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experienceTracy L Rose, William H Weir, Gregory M Mayhew, et al.
Cancer|December 21, 2018
Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genesPetros Grivas, Amir Mortazavi, Joel Picus, et al.
Science (New York, N.Y.)|August 28, 2012
Genome sequencing identifies a basis for everolimus sensitivityGopa Iyer, Aphrothiti J Hanrahan, Matthew I Milowsky, et al.
Clinical Genitourinary Cancer|July 19, 2014
Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinomaGuru Sonpavde, Joaquim Bellmunt, Jonathon E Rosenberg, et al.
European Urology|November 7, 2021
The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial CarcinomaRichard Cathomas, Anja Lorch, Harman M Bruins, et al.
British Journal of Cancer|March 12, 2022
Correction to: Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experienceTracy L Rose, William H Weir, Gregory M Mayhew, et al.
The Journal of Clinical Investigation|August 24, 2018
Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinomaChristof C Smith, Kathryn E Beckermann, Dante S Bortone, et al.
Pageof 21

Showing results (151-160 of 205) with videos related to

Sort By:
Pageof 21
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 21, 2022
Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO GuidelineW Kimryn Rathmell, R Bryan Rumble, Peter J Van Veldhuizen, et al.
Journal for Immunotherapy of Cancer|August 16, 2017
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinomaAshish M Kamat, Joaquim Bellmunt, Matthew D Galsky, et al.
Acta Oncologica (Stockholm, Sweden)|August 31, 2017
Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) InvestigatorsJihane Boustani, Aurélie Bertaut, Matthew D Galsky, et al.
British Journal of Cancer|July 23, 2021
Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experienceTracy L Rose, William H Weir, Gregory M Mayhew, et al.
Cancer|December 21, 2018
Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genesPetros Grivas, Amir Mortazavi, Joel Picus, et al.
Science (New York, N.Y.)|August 28, 2012
Genome sequencing identifies a basis for everolimus sensitivityGopa Iyer, Aphrothiti J Hanrahan, Matthew I Milowsky, et al.
Clinical Genitourinary Cancer|July 19, 2014
Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinomaGuru Sonpavde, Joaquim Bellmunt, Jonathon E Rosenberg, et al.
European Urology|November 7, 2021
The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial CarcinomaRichard Cathomas, Anja Lorch, Harman M Bruins, et al.
British Journal of Cancer|March 12, 2022
Correction to: Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experienceTracy L Rose, William H Weir, Gregory M Mayhew, et al.
The Journal of Clinical Investigation|August 24, 2018
Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinomaChristof C Smith, Kathryn E Beckermann, Dante S Bortone, et al.
Pageof 21